a Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina
b Department of Pediatrics, Emory University, Atlanta, Georgia
c Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio
d Research Triangle Institute, Research Triangle Park, North Carolina
e Brown University, Rhode Island Hospital, Providence, Rhode Island
f National Institute of Child Health and Human Development, Bethesda, Maryland
g University of Miami, Jackson Memorial Hospital, Miami, Florida
BACKGROUND. Neonatal candidiasis is associated with substantial morbidity and mortality rates. Neurodevelopmental follow-up data for a large multicenter cohort have not been reported.
METHODS. Data were collected prospectively for neonates born at <1000 g at National Institute of Child Health and Human Development-sponsored Neonatal Research Network sites between September 1, 1998, and December 31, 2001. Uniform follow-up evaluations, including assessments of mental and motor development with the Bayley Scales of Infant Development II, were completed for all survivors at corrected ages of 18 to 22 months. We evaluated risk factors for the development of neonatal candidiasis, responses to antifungal therapy, and the association between candidiasis and subsequent morbidity and death.
RESULTS. The cohort consisted of 4579 infants; 320 of 4579 (7%) developed candidiasis; 307 of 320 had Candida isolated from blood, 27 of 320 had Candida isolated from cerebrospinal fluid, and 13 (48%) of 27 of those with meningitis had negative blood cultures. In multivariate analysis of risk factors on day of life 3, birth weight, cephalosporins, gender, and lack of enteral feeding were associated with development of candidiasis. After diagnosis, most neonates had multiple positive cultures despite antifungal therapy, and 10% of neonates had candidemia for
14 days. Death or neurodevelopmental impairment (NDI) was observed for 73% of extremely low birth weight infants who developed candidiasis. Death and NDI rates were greater for infants who had delayed removal or replacement of central catheters (>1 day after initiation of antifungal therapy), compared with infants whose catheters were removed or replaced promptly.
CONCLUSIONS. Blood cultures were negative for approximately one half of the infants with Candida meningitis. Persistent candidiasis was common. Delayed catheter removal was associated with increased death and NDI rates.
Key Words: candidiasis meningitis sensitivity specificity culture premature infant
Abbreviations: CSFcerebrospinal fluid CIconfidence interval DOLday of life EGAestimated gestational age ELBWextremely low birth weight IVHintraventricular hemorrhage NDI neurodevelopmental impairment MDIMental Developmental Index ORodds ratio PDApatent ductus arteriosus PDIPsychomotor Developmental Index
This article has been cited by other articles:
![]() |
L Clerihew and W McGuire Antifungal prophylaxis for very low birthweight infants: UK national survey Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2008; 93(3): F238 - F239. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Healy, J. R. Campbell, E. Zaccaria, and C. J. Baker Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species Pediatrics, April 1, 2008; 121(4): 703 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Benjamin Jr First, Do No Harm Pediatrics, April 1, 2008; 121(4): 831 - 832. [Full Text] [PDF] |
||||
![]() |
C. J. Ragouilliaux, S. E. Keeney, H. K. Hawkins, and J. L. Rowen Maternal Factors in Extremely Low Birth Weight Infants Who Develop Spontaneous Intestinal Perforation Pediatrics, December 1, 2007; 120(6): e1458 - e1464. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A McCrossan, E. McHenry, F. O'Neill, G. Ong, and D. G Sweet Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2007; 92(6): F454 - F458. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Manzoni, I. Stolfi, L. Pugni, L. Decembrino, C. Magnani, G. Vetrano, E. Tridapalli, G. Corona, C. Giovannozzi, D. Farina, et al. A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates N. Engl. J. Med., June 14, 2007; 356(24): 2483 - 2495. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Burwell, D. Kaufman, J. Blakely, B. J. Stoll, and S. K. Fridkin Antifungal Prophylaxis to Prevent Neonatal Candidiasis: A Survey of Perinatal Physician Practices Pediatrics, October 1, 2006; 118(4): e1019 - e1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Cotten, S. McDonald, B. Stoll, R. N. Goldberg, K. Poole, D. K. Benjamin Jr, and on behalf of the National Institute for Child Heal The Association of Third-Generation Cephalosporin Use and Invasive Candidiasis in Extremely Low Birth-Weight Infants Pediatrics, August 1, 2006; 118(2): 717 - 722. [Abstract] [Full Text] [PDF] |
||||